Incidence and survival of castration-resistant prostate cancer patients with visceral metastases: results from the Dutch CAPRI-registry

Cornford P, Bellmunt J, Bolla M, Briers E, De Santis M, Gross T, et al. EAU-ESTRO-SIOG guidelines on Prostate Cancer. Part II: treatment of relapsing, metastatic, and castration-resistant Prostate Cancer. Eur Urol. 2017;71:630–42.

Article  Google Scholar 

Eisenberger M, Blumenstein B, Crawford E, Miller G, McLeod D, Loehrer P, et al. Bilateral orchiectomy with or without flutamide for metastatic Prostate Cancer. N. Engl J Med. 1998;339:1036–42.

Article  CAS  Google Scholar 

Pezaro C, Omlin A, Lorente D, Nava Rodrigues D, Ferraldeschi R, Bianchini D, et al. Visceral disease in castration-resistant Prostate Cancer. Eur Urol. 2014;65:270–3.

Article  CAS  Google Scholar 

Westgeest H, Uyl-de Groot C, van Moorselaar R, de Wit R, van den Bergh A, Coenen J, et al. Differences in trial and real-world populations in the Dutch Castration-resistant Prostate Cancer Registry. Eur Urol Focus. 2018;4:694–701.

Article  Google Scholar 

Whitney C, Howard L, Posadas E, Amling C, Aronson W, Cooperberg M, et al. In men with castration-resistant Prostate Cancer, visceral metastases predict shorter overall survival: what predicts visceral metastases? Results from the SEARCH database. Eur Urol Focus. 2017;3:480–6.

Article  Google Scholar 

Halabi S, Kelly W, Ma H, Zhou H, Solomon N, Fizazi K, et al. Meta-analysis evaluating the impact of site of metastasis on overall survival in men with Castration-Resistant Prostate Cancer. J Clin Oncol. 2016;34:1652–9.

Article  CAS  Google Scholar 

van Dodewaard-de Jong J, Verheul H, Bloemendal H, de Klerk J, Carducci M, van den Eertwegh A. New treatment options for patients with metastatic Prostate Cancer: what is the optimal sequence? Clin Genitourin Cancer. 2015;13:271–9.

Article  Google Scholar 

Hussain M, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, et al. Survival with olaparib in metastatic castration-resistant Prostate Cancer. N. Engl J Med. 2020;383:2345–57.

Article  CAS  Google Scholar 

Annala M, Fu S, Bacon J, Sipola J, Iqbal N, Ferrario C, et al. Cabazitaxel versus abiraterone or enzalutamide in poor prognosis metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase II trial. Ann Oncol. 2021;32:896–905.

Article  CAS  Google Scholar 

de Wit R, de Bono J, Sternberg C, Fizazi K, Tombal B, Wülfing C, et al. Cabazitaxel versus abiraterone or enzalutamide in metastatic Prostate Cancer. N. Engl J Med. 2019;381:2506–18.

Article  Google Scholar 

Corn PG, Heath EI, Zurita A, Ramesh N, Xiao L, Sei E, et al. Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1–2 trial. Lancet Oncol. 2019;20:1432–43.

Article  CAS  Google Scholar 

White I, Royston P, Wood A. Multiple imputation using chained equations: issues and guidance for practice. Stat Med. 2010;30:377–99.

Hanyok B, Howard L, Amling C, Aronson W, Cooperberg M, Kane C, et al. Is computed tomography a necessary part of a metastatic evaluation for castration-resistant prostate cancer? Results from the shared equal access Regional Cancer Hospital Database. Cancer. 2015;122:222–9.

Article  CAS  Google Scholar 

Shenderov E, Velho P, Awan A, Mirkheshti N, Eisenberger M, Pardoll D, et al. Genomic characterization of pulmonary-metastatic prostate cancer: a unique molecular subtype. J Clin Oncol. 2019;37:210–10.

Article  Google Scholar 

Alshalalfa M, Seldon C, Franco I, Vince R, Carmona R, Punnen S, et al. Clinicogenomic characterization of prostate cancer liver metastases. Prostate Cancer and Prostatic Dis. 2022;25:366–9.

Article  CAS  Google Scholar 

Halabi S, Lin C, Kelly W, Fizazi K, Moul J, Kaplan E, et al. Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant Prostate Cancer. J Clin Oncol. 2014;32:671–7.

Article  Google Scholar 

Halabi S, Lin C, Small E, Armstrong A, Kaplan E, Petrylak D, et al. Prognostic model predicting metastatic castration-resistant Prostate Cancer survival in men treated with second-line chemotherapy. JNCI J Natl Cancer Inst. 2013;105:1729–37.

Article  CAS  Google Scholar 

留言 (0)

沒有登入
gif